Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

ent. 

About Evolocumab (AMG 145)
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).1 PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.2 Evolocumab, being developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9 binding to LDL receptors on the liver's surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood.1

Amgen has obtained the issuance of two U.S. patents related to evolocumab: USP 8,030,457 and USP 8,563,698. These patents will expire in 2029 but some extension period may be available, subject to certain regulatory conditions and statutory provisions for patent term extension.  

About PROFICIO: The Evolocumab Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large and comprehensive clinical trial program evaluating evolocumab. Phase 3 clinical trials for evolocumab are currently underway and build upon the Phase 2 studies.

The Phase 3 program includes 13 trials, with a combined planned enrollment of more than 28,000 patients. The Phase 3 studies will evaluate evolocumab administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with hyperlipidemia (LAPLACE-2), in patients with hyperlipidemia who cannot tolerate statins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.

Five s
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... underwritten offerings of 10,000,000 shares of its Common Stock ... share, for expected gross proceeds of $20 million and ... at a price to the public of $2,000.00 per ... share of Series A Convertible Preferred Stock is non-voting ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... seeking to improve their vision. What sets the Trusted ... ensuring that only those who are among the best ... the United States are listed. Refractive eye surgeons, ...
... well-known dangers of first- and secondhand smoke, an estimated ten ... Exposure of a developing baby to harmful cigarette byproducts from ... and poses a significant health care burden. , Now, in ... has completed a global assessment of newborns, umbilical cord blood ...
... ST. LOUIS, Dec. 3 Sigma-Aldrich (Nasdaq: ... leading producer of single-wall,carbon nanotubes, announced today that ... distribute SWeNT,s single-wall carbon nanotubes to,the research and ... Under the terms of the agreement, Sigma-Aldrich ...
Cached Biology Technology:Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 2Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 3Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 4Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 5Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 6Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 7Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes 2Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes 3
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... are among the most important fruit trees in the world. ... be more than 4,000 years. Until now, however, the exact ... Citrus sinensis ), lemon ( C. limon ), and grapefruit ... of researchers from China has published a study in the ...
... COLUMBIA, ... avoid workouts, stay inside and overindulge in comfort foods. However, health ... leave most people feeling less content during the winter months. MU ... avoid wintertime woes. Instead of resolving to make ...
... LA JOLLA, CAMutant presenilin is infamous for its role ... Alzheimer,swhich can strike people as early as their 30s. ... uncovered presenilin,s productive side: It helps embryonic motor neurons ... and hem them in on their way to their ...
Cached Biology News:Genetic origin of cultivated citrus determined 2Establish healthy traditions to make winter fun, prevent cold-weather blues 2Unlocking the secret(ase) of building neural circuits 2Unlocking the secret(ase) of building neural circuits 3